Myung in Pharm Co., Ltd.

Myung in Pharm Co., Ltd.

KKRX:317450
42,100.00
KRW
-100.00
(-0.24%)
6,432.21EPS
6.46P/E
606.63BMarket Cap

Total Valuation

KRW

As of June 30, 2026, Myung in Pharm Co., Ltd. carries a market capitalization of 606.63B, placing it among publicly traded companies globally. Its enterprise value stands at 137.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap606.63B
Enterprise Value137.61B

Share Statistics

As of June 30, 2026, Myung in Pharm Co., Ltd. has 14.60M shares outstanding.

Shares Outstanding14.60M

Valuation Ratios

As of June 30, 2026, Myung in Pharm Co., Ltd. trades at a trailing price-to-earnings ratio of 6.46. The price-to-sales ratio is 1.96, and the price-to-book ratio stands at 0.74.

PE Ratio6.46
PS Ratio1.96
PB Ratio0.74
P/TBV Ratio0.75
P/FCF Ratio19.33
P/OCF Ratio7.37

Enterprise Valuation

As of June 30, 2026, Myung in Pharm Co., Ltd. trades at an EV/EBITDA multiple of 1.27 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 1.40 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Myung in Pharm Co., Ltd. trades at an EV/FCF ratio of 4.61, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 137.61B versus a market cap of 606.63B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.47
EV / EBITDA1.27
EV / EBIT1.40
EV / FCF4.61

Financial Position

As of June 30, 2026, Myung in Pharm Co., Ltd. maintains a current ratio of 12.40, meaning it holds 12.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.12, indicating conservative leverage, while an interest coverage ratio of 483.94 demonstrates strong ability to service its debt obligations.

Current Ratio12.40
Quick Ratio9.40
Debt / Equity0.12
Debt / EBITDA0.01
Interest Coverage483.94

Financial Efficiency

KRW

These figures cover the twelve months ended June 30, 2026. The company generates approximately 550.81M in revenue per employee across its workforce of 532.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee550.81M
Employee Count532.00

Taxes

KRW

Over the twelve months ended June 30, 2026, Myung in Pharm Co., Ltd. recorded 23.90B in income tax expense. That works out to an effective tax rate of 21.19, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 112.75B, leaving 88.85B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax23.90B
Effective Tax Rate21.19

Stock Price Statistics

KRW

As of the close on November 17, 2026, Myung in Pharm Co., Ltd.'s stock has declined approximately 41.20% over the past 52 weeks. The 50-day moving average sits at 42,091.00, while the 200-day moving average is 49,281.50.

52-Week Price Change-41.20%
50-Day Moving Average42,091.00
200-Day Moving Average49,281.50

Income Statement

KRW

Over the twelve months ended June 30, 2026, Myung in Pharm Co., Ltd. generated 293.03B in revenue and converted that into 88.85B in net income, yielding earnings per share of 6,432.21. EBITDA reached 108.47B, while operating income came in at 98.31B.

Revenue293.03B
Gross Profit181.00B
Operating Income98.31B
Pretax Income112.75B
Net Income88.85B
EBITDA108.47B
EBIT98.31B
Earnings Per Share (EPS)6,432.21

Balance Sheet

KRW

As of June 30, 2026, Myung in Pharm Co., Ltd. holds 470.00B in cash and equivalents against 982.84M in total debt, resulting in a net debt position of -26.70B. Total book value stands at 816.37B, with working capital of 570.20B providing operational flexibility.

Cash & Cash Equivalents470.00B
Total Debt982.84M
Net Debt-26.70B
Equity (Book Value)816.37B
Book Value Per Share55,915.44
Working Capital570.20B

Cash Flow

KRW

Myung in Pharm Co., Ltd. produced 77.88B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -48.19B in capital expenditures, free cash flow totaled 29.69B - equivalent to 2,149.63 per share.

Operating Cash Flow77.88B
Capital Expenditures-48.19B
Free Cash Flow29.69B
FCF Per Share2,149.63

Margins

Over the twelve months ended June 30, 2026, Myung in Pharm Co., Ltd. posted a gross margin of 61.77, reflecting its pricing power and cost economics. The operating margin of 33.55 and net profit margin of 30.32 provide insight into operational efficiency.

Gross Margin61.77
Operating Margin33.55
Pretax Margin38.48
Profit Margin30.32
EBITDA Margin37.02

Dividends & Yields

Over the twelve months ended June 30, 2026, Myung in Pharm Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.17, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -28.09, meaning Myung in Pharm Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-28.09
FCF Yield5.17

Scores

As of June 30, 2026, Myung in Pharm Co., Ltd. has an Altman Z-Score of 9.52, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score9.52